Individuals with ASD often have comorbid issues (disease or disorder that occurs at the same time as another disorder or illness) and these can often be a challenge to diagnose and treat. Learn more about these conditions, how you can test for and treat them, and what impact, if any, these may have on symptoms of ASD.
Conventional psychiatric medications, including SSRIs and benzodiazepines, may not be effective for everyone with anxiety disorders. Others may find only partial relief with these medications or experience unpleasant side effects. In this 60-minute presentation Suruchi Chandra, M.D. describes a whole-body approach to identifying the core imbalances underlying anxiety disorders, including the gut-brain connection, hormonal imbalances, immune system dysfunction, mitochondrial dysfunction, and methylation defects. She also discusses ways to treat anxiety by addressing these underlying metabolic imbalances.
Knowlege Quiz & Certificate
Presenter Biography: Suruchi Chandra, M.D. Dr. Chandra is a board certified psychiatrist who uses an integrative and holistic approach to help those with challenging psychological and behavioral issues. She has an undergraduate degree from Harvard and a medical degree from Yale University. After medical school, she completed a psychiatry residency at the Massachusetts General Hospital/McLean Hospital combined program at Harvard Medical School. She also has extensive training in integrative and holistic approaches. She has spoken at numerous conferences, including the Advisory Board on Autism and Related Disorders, the Autism Society of America, and the Autism Research Institute.
Current evidence points to an increase in inflammation markers and oxidative stress in individuals with ASD. Hear Andrew Zimmerman, MD discuss changes in the brain associated with autism spectrum disorders followed by live Q&A.
Andrew Zimmerman, MD specializes in neurodevelopmental disability, neurology, pediatric neurology, and psychiatry. He is a Clinical Professor of Pediatrics, University of Massachusetts Medical School.
Knowledge Quiz & Certificate
Medical diagnostic coding books have historically defined autism as a psychiatric or behavioral disorder. However, autism is not a psychiatric disorder, but a medical disorder with neurobehavioral symptomatology. In fact, it appears to be a chronic systemic inflammatory disorder that also affects the brain. Furthermore, autism is not a single entity, but rather a spectrum with multiple phenotypes (physical presentations) and multiple factors that contribute to its variable symptomatology. Using various biomarkers allows us to subtype the so-called “autisms” and further understand the underlying imbalances — metabolic, immunologic, neurologic and gastrointestinal. We can then use this knowledge to help craft individualized biomedical treatment programs, which, when coupled with behavioral, clinical and educational interventions, offer realistic hope for improvement for affected children and their families.
HANDOUTS in .pdf format (this is a large file and will take some time to download)
Explanation: ARI collected two samples from the same person at the same time, and sent both samples to the lab for testing (without the lab’s knowledge). This was done for at least 2 people for every test (four or more total samples). The results from the lab were then analyzed to determine how closely they were able to reproduce the same results for the same person. To receive a Pass, we required no more than 10% of the tests had a minor error (differ by 30-50% of the reference range) and no more than 10% of the tests had a major error (differ by 50% or more). We use the reference range instead of the absolute value because some tests have very narrow reference ranges, so it is important to interpret differences in terms of the reference range.
Read Full Report (.pdf)
Integrative Treatments for ASD
The word biomedical means that the fundamental principle of biology—the individuality of each living creature—is the first consideration in the medical treatment options for each patient. Thirty-five years of such consideration and common sense combine to form two biomedical questions that capture my thinking about the best path to recovery for each person.
- Does this person have a special unmet need to get something beneficial?
- Does this person have a special unmet need to avoid or get rid of something allergenic or toxic?
These questions arise when we start the easy first steps of inquiry by asking, “What is the best initial diagnostic/treatment step?” (In other words, on day one we don’t need to decide on the whole plan, just today’s answer to today’s question: what is the best first step?) The same “get and get rid of” questions apply with each subsequent step and recur when we arrive at the difficult ultimate question: “Have we done everything we can for this person?”
Biomedical is a way of thinking about medical problem-solving, not a fixed set of tests and treatments. The subject of biomedical thinking is the individual, the details of whose story provide the grist for the mill that delivers treatment options. There is no one-size-fits-all biomedical treatment protocol for autism. But there is a biomedical approach to the treatment of each individual child in the spectrum, just as there is for prevention and treatment of chronic illness in general. Getting the questions right is more important than getting the label or diagnosis right. The patient—not the “protocol”—is the expert and expresses his or her expertise by responses to tests and treatments which become the guide for further understanding of the options.
If therapeutic options for each child spring from the details of the child’s history, physical exam, and lab tests and not from a label, then what good is the label or the diagnostic grouping that it names? Diagnostic criteria, relatively unimportant for driving treatment decisions in an individual child, form the basis for research showing general differences between children in the autism spectrum and normal controls.
What are the biggest differences? Among all the many laboratory and clinical measurements showing significant differences between groups of children with autism and groups of normal children, three biochemical areas stand out, giving us a framework for understanding causes and treatments for many individuals—individuals who will still differ among themselves in the way these areas interact and respond to treatment. The group differences in the research studies I refer to are many fold and therefore demand our attention in ways that would not be the case if the differences were a matter of, say, 15 to 30 percent (a usual threshold for belief that a measured difference is real). Such small but significant differences between normal and autistic children abound and provide the basis for what Boyd Haley, Ph.D. has termed the “biochemical train wreck” of autism. The few major differences between groups of autistic and groups of normal children give us insight into the cause and prevention of the train wreck and should serve as a guide to research and public policy as well as individual biomedical questions.
The three processes in which huge differences are found are pictured in the Venn diagram below. The overlap features a particular molecule GHS (glutathione) whose chemistry is central in all three areas. Difficulties of children in the autism spectrum with respect to detoxification, inflammation and oxidative stress have been studied, described, presented and published, leaving no room for doubt that these three interconnected domains are crucial to understanding the origins and treatments of our children’s problems.
The same diagram describes the chemistry of the major diseases of modern affluent industrialized societies (cardiovascular, cancer, auto-immune, dementia, etc.). It is credible therefore that autism is not a separate problem from all the other diseases of affluent societies in which disturbed ecological balance triggers vicious cycles in the chemistry of inflammation, detoxication and oxidative adaptation. This understanding of the biochemical and ecological context of the autism epidemic moves us away from the current medical paradigm of name-it, blame-it, and tame-it prescription-pad medicine toward a systems approach that focuses on each child as an individual. Such an approach has led to the recovery of thousands of children.
How does biomedical differ from just plain medical? Medical language and thinking are disease-oriented and begin with an effort to understand how to group individuals according to their similarities as defined by signs, symptoms and tests. We speak of “disease entities” that subject their “victims” to “attack.” This is the lingo of sudden, short-lived illnesses that characterized medical practice until about a century ago. There is not much point in quibbling about the way we speak about catching a cold, coming down with measles, or fracturing a collar bone. Giving a suitable name is close to the full expression of our understanding of the process of the acute infection or trauma that produced the illness. It’s not so with chronic illness in which the mechanism is obscure and the name is a description. I do not mean to imply that a descriptive name is a bad thing—we are all reassured by any implication that “they know what I’ve got.” Even a scary name can be better than uncertainty. Especially in children, however, the naming and predicting that go with labels like autism have been a disaster for many families because the name has foreclosed the biomedical questions and the predictions have cut off hope and intention, two key ingredients of inspired clinical decisions and healing.
I do not know how biomedical came into the vocabulary of those of us who have started and nurtured the Defeat Autism Now! Project within the Autism Research Institute. The term is generally used for a field of engineering in which human capacities are extended by the use of mechanical or electronic devices. As the word is used now in relation to autism it wrongly implies to some the implication of “alternative’ or fringe medicine. There is no such thing as alternative biochemistry or alternative immunology, the two medical disciplines that overlap in the Venn Diagram and form the basis for our clinical approach to children in the autism spectrum.
The biomedical approach to patients is nothing more than common sense as expressed by questions acknowledging the basic biological fact of individuality, which is Nature’s most powerful adaptive strategy. The term biomedical should convey a sense of rejection of the utter nonsense of at least one aspect of current mainstream medicine: the acceptance of the notion that you can take a group of people who are sick in similar ways, give a descriptive name such as autism, colitis, depression, etc. to the group, and then say that the symptoms are caused by the name. If engineers talked that way, bridges would all fall down and the cause would be some translation into Greek or Latin of “Fally-Down Bridge Disease.” Everyone would laugh at them—but they don’t scoff when people say that “autism” is making your kid speechless, self-injurious, or physically ill. In our opinion, they should.
Author Biography: Sidney Baker, M.D., with the support of ARI, developed Autism 360. Dr. Baker is the co-founder of the ARI Conference; he has written many books including ARI’s publication Autism: Effective Biomedical Treatments (co-written with Dr. Jon Pangborn); and he is one of the leading clinicians in the field of autism. Dr. Rimland was very excited about Dr. Baker’s Medigenesis project, and several years ago he wrote an editorial about this project. We encourage you to learn more about Medigenesis at Medigenesis.com.